Company Overview

REMSleep Holdings, Inc. is a U.S.-based company focused on the medical devices and sleep health industry. The company’s core business centers on the development, marketing, and distribution of non-invasive therapeutic devices designed to address sleep-disordered breathing, particularly snoring and mild obstructive sleep apnea. REMSleep Holdings positions itself within the broader sleep technology and respiratory care market, targeting both clinical and consumer healthcare segments.

The company’s primary product offering is the DeltaWave® oral appliance, a patented mandibular advancement device intended to reduce snoring and improve airflow during sleep. REMSleep Holdings operates as a publicly traded micro-cap company on the OTC Markets. Its strategy emphasizes affordability, ease of use, and accessibility compared with traditional CPAP therapy. Public disclosures indicate the company has undergone multiple restructurings and strategic refocusing efforts since its early years, evolving from a broader health technology concept into a more narrowly defined sleep-device company. Data inconclusive based on available public sources regarding consistent revenue scale or profitability.

Business Operations

REMSleep Holdings generates revenue primarily through the sale and licensing of its DeltaWave® oral sleep appliance, distributed via dental professionals, healthcare providers, and direct-to-consumer channels. Operations include product development, regulatory compliance, intellectual property management, and limited-scale commercialization. The company relies on third-party manufacturing partners rather than owning large-scale production facilities, which aligns with its asset-light operating model.

The company’s operations are predominantly domestic, with sales and marketing activities concentrated in the United States. Public filings reference efforts to expand professional dental networks and online distribution platforms. There is limited publicly verified information regarding recurring revenue contracts, long-term supply agreements, or material joint ventures. Data inconclusive based on available public sources regarding the scale of international operations or technology licensing revenue.

Strategic Position & Investments

Strategically, REMSleep Holdings focuses on expanding adoption of oral appliance therapy as an alternative to CPAP machines, emphasizing patient compliance and comfort. Growth initiatives disclosed in public filings include broader market education, expanded dental practitioner outreach, and incremental product enhancements tied to existing patents. The company has highlighted its intellectual property portfolio as a core strategic asset.

Public records do not show significant recent acquisitions or large capital investments in unrelated businesses. REMSleep Holdings does not report ownership of notable subsidiaries or a diversified investment portfolio. Its strategic direction appears centered on organic growth rather than mergers and acquisitions. Data inconclusive based on available public sources regarding large-scale institutional investment or long-term strategic partnerships.

Geographic Footprint

REMSleep Holdings is headquartered in the United States, with its principal executive offices located domestically. The company’s operational footprint is primarily national, with product availability and marketing focused on U.S. healthcare providers and consumers.

While company materials reference potential global applicability of its sleep solutions, there is limited verified evidence of sustained commercial operations in Europe, Asia-Pacific, or other international regions. Any international exposure appears exploratory rather than operationally material. Data inconclusive based on available public sources regarding meaningful overseas revenue contribution.

Leadership & Governance

REMSleep Holdings is led by an executive team responsible for corporate strategy, product commercialization, and regulatory compliance. Leadership disclosures emphasize operational efficiency and intellectual property monetization within a highly regulated medical device environment. The company operates under a standard public-company governance framework appropriate for OTC-listed issuers.

Key executives include:

• Stewart B. Dunlap – Chief Executive Officer
• William J. Moore – Chief Financial Officer
• David A. Hulslander – Director

Public disclosures do not consistently identify additional long-tenured executive officers or independent board committee structures. Data inconclusive based on available public sources regarding broader governance practices, executive succession planning, or formalized leadership philosophy statements.